WOCKPHARMAWockhardt Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on WOCKPHARMA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • Revenue growth: 36.4% YoY
- • Profit growth: 553.2% YoY
- • Debt/Equity: 0.42
- • RSI: 64
- • MACD: bullish
- • Price vs EMA21: above
Bull case
- • Revenue growth: 36.4% YoY
- • Profit growth: 553.2% YoY
- • Debt/Equity: 0.42
- • RSI: 64
Bear case
- • ROE: 4.0%
- • ROCE: 5.6%
- • Volatility: 52% annualized
Key risks
- • ROE: 4.0%
- • ROCE: 5.6%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹80.23). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.